vimarsana.com

Page 183 - உலகளாவிய நட்சத்திரம் பயணம் மேலாண்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vaccine diplomacy boosts Russia s and China s global standing

Greater SCO synergy will foster economic development, say experts

Greater SCO synergy will foster economic development, say experts By XIE CHUANJIAO in Qingdao, Shandong | China Daily | Updated: 2021-04-30 09:08 Visitors look at exhibits at the 2021 SCO International Investment and Trade Expo in Qingdao, Shandong province. [Photo/Xinhua] Enhanced efforts to boost cooperation among the Shanghai Cooperation Organization member states will boost economic development in the region, officials and experts said. The SCO, which is celebrating its 20th anniversary this year, has become an important platform for bilateral and multilateral trade and economic cooperation, and is now a leading global economic development center, Vladimir Norov, secretary-general of the SCO, said during the opening ceremony of the 2021 SCO International Investment and Trade Expo held in Qingdao, Shandong province.

Welcome To IANS Live - INTERNATIONAL - 1 bn Covid vax unprecedented feat, but disparities exists

通用将投资10亿美元在墨西哥生产电动汽车

通用将投资10亿美元在墨西哥生产电动汽车
sina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.cn Daily Mail and Mail on Sunday newspapers.

Biocon posts profit of ₹254 crore for Q4 - The Hindu BusinessLine

Biocon posts profit of ₹254 crore for Q4 April 29, 2021 Performance driven by biosimilars, research services and generics businesses Global biopharma company Biocon Limited has posted 106.50 per cent profit for the fourth quarter (Q4) of FY 2020-21 on a consolidated basis, at ₹254 crore as against ₹123 crore posted last year, driven by biosimilars, research services and generics businesses. The company’s revenues are higher by 26 per cent, at ₹2,044 crore as against ₹1,621 crore in the same period last year. The company has gained ₹160 crore arising on the fair valuation of Bicara Therapeutics Inc (Bicara) due to loss of control from subsidiary to associate reported under ‘other income’ for the quarter.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.